Crown Bioscience houdt symposium over precisiegeneeskunde en oncologisch onderzoek vertalen naar klinisch succes
SANTA CLARA, Calif.–(BUSINESS WIRE)– Crown Bioscience houdt op 10 februari 2016 een symposium in The Nucleus in Chesterford Research Park. Crown Bioscience is een internationaal bedrijf in medicijnonderzoek en -ontwikkeling dat translationele platforms aanbiedt ter bevordering van onderzoek naar kanker en metabole ziekten.
Het symposium, Precision Medicine: Translating Oncology Drug Discovery into Success in the Clinic, gaat over de implementatie van translationele technologieën binnen de wetenschappelijke en medische wereld ter verbetering van de ontwikkeling van medicijnen voordat deze klinisch worden gekeurd. Dit helpt bij het nemen van klinische beslissingen en vergroot de klinische waarde.
“Ons doel is wetenschappers de mogelijkheid bieden de nieuwste wetenschappelijke benaderingswijzes in immuno-oncologie en gecombineerde therapeutische regimes te delen, waardoor de beste kandidaten snel het klinische ontwikkelingsproces ingaan”, zei Jean-Pierre Wery, president van Crown Bioscience.
Crown Bioscience to Hold Symposium on Precision Medicine and Translating Oncology Drug Discovery into Success in the Clinic |
|||||
|
SANTA CLARA, Calif.–(BUSINESS WIRE)– Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology andmetabolic disease research, will be hosting a symposium at The Nucleus in Chesterford Research Park, UK, on Feb. 10, 2016. The symposium, “Precision Medicine: Translating Oncology Drug Discovery into Success in the Clinic,” will focus on the implementation of translational technologies across the research and clinical communities to improve the development of drugs before entering clinical trials, to support clinical decisions and to maximize clinical value. “Our goal is to create an opportunity for leading scientists to share the latest scientific approaches in immuno-oncology and combination therapeutic regimes to help speed the best candidates to clinical development,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. As an end-to-end preclinical to clinical service provider and thought leader in translational oncology, CrownBio has made a significant investment to improving the knowledge of the scientific community about translational platforms. The company has assembled a notable line-up of eight industry experts, including Dr. Gary Middleton, professor of medical oncology at University of Birmingham, and Dr. Thomas Mehrling, managing director of Mundipharma-EDO GmbH. The symposium will also feature CrownBio’s Dr. Rajendra Kumari, chief scientific officer, and Dr. Eric Murphy, global scientific director for translational oncology. The event will be free to attend, but there are a limited number of places. To register, send an email to busdev@crownbio.com with a request to join the event. For more information about the symposium and Crown Bioscience’s commitment to improving clinical outcomes, visit www.crownbio.com/news/events. About Crown Bioscience Inc. Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005043/en/ Contacts For Crown Bioscience Inc. |
|||||